新型口服抗凝药物达比加群和利伐沙班相关出血的应对

中国药物警戒 ›› 2014, Vol. 11 ›› Issue (1): 15-18.

新型口服抗凝药物达比加群和利伐沙班相关出血的应对

文力,韩兴,周浩,张新超^*

卫生部北京医院急诊科,北京 100730

收稿日期:2016-02-03 修回日期:2016-02-03 出版日期:2014-01-08 发布日期:2016-02-03
通讯作者: 张新超,男,博士,主任医师,心脏病学与重症医学。
作者简介:文力,男,主治医师,心脏病学与重症医学。

The Management of Hemorrhage Lead by New Oral Anticoagulants Dabigatran and Rivaroxaban

WEN Li, HAN Xing, ZHOU Hao, ZHANG Xin-chao^*

Division of Emergency Medicine, Beijing Hospital, Beijing 100730, China

Received:2016-02-03 Revised:2016-02-03 Online:2014-01-08 Published:2016-02-03

摘要/Abstract

摘要： 近几年各类新型的口服抗凝药物陆续投入临床使用,其中最具代表性的药物是直接Xa因子抑制剂利伐沙班和直接凝血酶抑制剂达比加群。由于它们特殊的作用机制和针对性拮抗药物的匮乏,给临床医师在处理相关出血情况时造成了困难。利伐沙班和达比加群的半衰期较短,目前针对这两种药物相关出血的主要处理措施是对症支持治疗和观察;但在出现危及生命的大出血时,可以采取凝血因子的替代治疗。

关键词: 血栓, 出血, 抗凝, 利伐沙班, 达比加群

Abstract: In recent years, various kinds of new oral anticoagulants(NOAC) have been put in use in clinic. One of the most representative drugs is a direct factor Xa inhibitor rivaroxaban and direct thrombin inhibitor dabigatran. Due to the short half-life of them, appropriate therapies include symptomatic supporting treatment and observation, which are likely to be effective for the majority of patients. In the case of life-threatening hemorrhage, clotting-factor substitutes may be appropriate in certain situations.

Key words: thrombus, hemorrhage, anticoagulant, rivaroxaban, dabigatran

中图分类号:

R973.2

文力,韩兴,周浩,张新超. 新型口服抗凝药物达比加群和利伐沙班相关出血的应对[J]. 中国药物警戒, 2014, 11(1): 15-18.

WEN Li, HAN Xing, ZHOU Hao, ZHANG Xin-chao. The Management of Hemorrhage Lead by New Oral Anticoagulants Dabigatran and Rivaroxaban[J]. Chinese Journal of Pharmacovigilance, 2014, 11(1): 15-18.

参考文献

[1] Vigué B.Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage from theory to practice[J].Crit Care,2009,13(2):209.
[2] Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update[J].J Thromb Thrombolysis, 2011,31(3):326-343.
[3] Zikria J, Ansell J. Oral anticoagulation with Factor Xa and thrombin inhibitors: is there an alternative to warfarin[J]. Discov Med, 2009,8(43):196-203.
[4] Mittal M K, Rabinstein A A. Anticoagulation?related intracranial hemorrhages[J]. Curr Atheroscler Rep, 2012,14(4):351-359.
[5] Prasad S, Wootten M R, Kulinski N, et al. What to do when warfarin therapy goes too far[J]. J Fam Pract, 2009, 58(7):346-352.
[6] Janssen Pharmaceuticals, Inc.Xarelto(rivaroxaban) prescribing information[S]. Titusville,NJ:2013:2-3.
[7] Johnson & Johnson Pharmaceutical Research & Development. Rivaroxaban for the prevention of stroke and non-central nervous system(CNS) systemic embolism in patients with atrial fibrillation[R]. Advisory committee briefing document, 2011:30-32.
[8] Turpie A G, Lassen M R, Davidson B L, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial[J].Lancet, 2009,373(9676): 1673-1680.
[9] Patel M R, Mahaffey K W, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med,2011,8(365): 883-891.
[10] Boehringer Ingelheim Pharma GmbH & Co. Pradaxa(dabigatran etexilate capsules) [package insert][S]. Germany:Ingelheim,2012:3-4.
[11] Bershad E M, Suarez J I. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage:a review of the literature[J]. Neurocrit Care,2010,12(3):403-413.
[12] Van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity[J]. Thromb Haemost, 2010,103(6):1116-1127.
[13] Hall A B, Carson B C. Reversal of warfarin-induced coagulopathy: review of treatment options[J]. J Emerg Nurs,2012,38(1):98-101.
[14] Gruber A, Marzec U M, Buetehorn U, et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates[J]. Blood,2008,112(8):3825.
[15] Perzborn E, Harwardt M. Recombinant factor VIIA partially reverses the effects of the factor XA inhibitor rivaroxaban on thrombin generation, but not the effects of thrombin inhibitors, in vitro[J]. J Thromb Haemost, 2007,5(suppl 2): Abstract P-W-640.
[16] Eerenberg E S, Kamphuisen P W, Sijpkens M K, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects[J]. Circulation, 2011,124(14):1573-1579.
[17] Eerenberg E S, Sijpkens M K, Kamphuisen P W, et al. Prothrombin complex concentrate reverses the anticoagulant effect of rivaroxaban in healthy volunteers[J]. Blood,2010,116(6):Abstract 1094.
[18] Patel M R, Maha ffey K W, G ar g J, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10):883-891.
[19] Guyatt G H, Norris S L, Schulman S, et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J]. Chest,2012,141(2 suppl):e89S-e119S.
[20] Cairns J A, Connolly S, McMurtry S, et al; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter[J]. Can J Cardiol, 2011,27(1):74-90.
[21] Bershad E M, Suarez J I. Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature[J]. Neurocrit Care,2010,12(3):403-413.